It is observed that Binex, which is suspected of changing the manufacturing of active pharmaceutical ingredients, has a strong expulsion from the KPBMA membership.

The KPBMA is expected to hold a meeting of the board of directors on the 16th and refer the agenda on the Binex situation to the ethics committee.

In a statement on the 11th, the KPBMA is highly likely to convene an ethics committee with the unanimous opinion of 14 directors and presidents in order to degrade K-Bio status and protect the right to public health.

If the board of directors' opinion is gathered on this day, the ethics committee will convene within 3 days at the latest, and it is expected that